Brief: Biocryst Announces Sale Of European Orladeyo(Berotralstat) Business To Neopharmed Gentili For Up To $264 Million
27/06/2025 12:14
June 27 (Reuters) - BioCryst Pharmaceuticals Inc BCRX.O: BIOCRYST ANNOUNCES SALE OF EUROPEAN ORLADEYO® (BEROTRALSTAT) BUSINESS TO NEOPHARMED GENTILI FOR UP TO $264 MILLION BIOCRYST PHARMACEUTICALS INC - NEOPHARMED GENTILI TO PAY BIOCRYST $250 MILLION UPFRONT FOR ORLADEYO BIOCRYST PHARMACEUTICALS INC - EXPECTS TO END 2027 WITH $700 MILLION IN CASH BIOCRYST PHARMACEUTICALS INC - TO USE PROCEEDS TO RETIRE ALL REMAINING TERM DEBT Source text: ID:nGNX149BKZ Further company coverage: BCRX.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on BioCryst Pharmaceuticals
See all newsUS RESEARCH ROUNDUP-Alnylam Pharmaceuticals, Carvana, MongoDB
Pharvaris' genetic disorder drug meets main goal in late-stage trial (updated)
Brief: Biocryst Announces Approval Of Orladeyo® For Pediatric Hae Patients In Japan
BioCryst Pharmaceuticals, Inc. reports results for the quarter ended June 30 - Earnings Summary
Brief: Biocryst Pharmaceuticals, - Cash, Cash Equivalents, Restricted Cash And Investments $354 Million At June 30, 2026